Ultrasound-guided ethanol injection for the treatment of parathyroid adenoma: A prospective self-controlled study

Amir Ali Yazdani1, Nooshin Khalili2, Mansour Siavash3, Albert Shemian4, Amir Reza Goharian2, Mozhgan Karimifar5, Babak Tavakoli4, Maryam Yazdi1,2

1Jam Medical Imaging and Interventional Radiology Center, Isfahan, Iran, 2Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran, 3Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, 4Arman Medical Imaging and Interventional Radiology Institute, Isfahan, Iran, 5Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

Background: Parathyroidectomy, the standard treatment of primary hyperparathyroidism (PHP) due to parathyroid adenoma, is not suitable for all patients. We evaluated the efficacy of ultrasound-guided ethanol ablation of parathyroid adenoma in a group of patients with PHP.

Materials and Methods: In a prospective self-controlled trial, 39 patients with parathyroid adenoma, who were not candidates for surgery, were enrolled. Ethanol injections were performed by two experienced interventional radiologists under the guidance of real-time ultrasonography. Adenoma size changes were assessed at about 1 month later. Serum levels of parathyroid hormone, calcium, phosphate, 25-OH Vitamin D, and alkaline phosphatase were evaluated at the baseline, 1, 3, 6, and 12 months after the injections. The treatment effects on outcome variables were assessed by repeated measures analysis.

Results: Volume of the adenomas decreased during the study period from 1.87±6.45 cm³ to 0.38±0.48 cm³ (P<0.001). Corrected serum calcium levels decreased from 10.40±0.96 mg/dl to 8.82±0.58 mg/dl (P<0.001), and remained stable during one year follow-up. Serum levels of parathyroid hormone decreased gradually from 129.85±63.37 to 72.58±53.86 pg/mL after 3 months and to 44.78±28.04 pg/mL after 1 year (P<0.001). Overall, 46% of the patients improved after 1 month of ethanol ablation therapy which increased to 84.5% during 1-year follow-up. No major complications were observed.

Conclusion: The current study showed the efficacy of ultrasound-guided ethanol injection in PHP and may be considered as a suitable alternative treatment in patients who are not candidates for the surgery. It has also a good safety profile without major complications if performed by experienced hands.

Key words: Ethanol ablation, hypercalcemia, parathyroid adenoma, primary hyperparathyroidism

INTRODUCTION

Primary hyperparathyroidism (PHP) is a common endocrine disorder, with worldwide incidence of 21.6 cases per 100,000.[1] The main cause of PHP is solitary adenoma (87%–91%), generally originating from chief cells,[2] although the other causes include hyperplasia (6%) and parathyroid carcinoma (<1%).[3] Parathyroid adenoma may present with hypercalcemia, kidney stone, osteoporosis, bone pain, depression, peptic ulcer, and many other clinical manifestations.[4] The standard treatment for parathyroid solitary adenoma or carcinoma is surgical excision.[5] However, surgical approach may not be appropriate for some patients due to clinical considerations, or it may fail in some patients.[6,7] Medical treatments, although may be effective, but does not usually lead to long-term sustained control of hypercalcemia and needs life-long therapy.[8]

Percutaneous ethanol injection treatment of parathyroid adenomas is introduced as an alternative therapeutic...
approach with a relatively high response rate which has been introduced in only some case reports.\textsuperscript{[9,10]} Moreover, little data are available concerning the long-term results of the percutaneous ethanol injection.\textsuperscript{[9]} On the other hand, direct injection of alcohol has some advantages which have not been studied as well, including lower costs as it is an outpatient procedure without needing general anesthesia, repeatability, and lack of interference with other therapeutic methods such as surgery. Finally, ethanol injection is a minimally invasive procedure with much less morbidity and mortality and few side effects in comparison to the surgery.\textsuperscript{[10]}

There are few prospective clinical trials about the efficacy of ethanol injection in the treatment of parathyroid adenoma and subsequent laboratory changes in the long term.\textsuperscript{[11,12]} In the current study, we evaluated and compared the clinical efficacy of percutaneous ethanol injection in the treatment of parathyroid adenoma through a prospective self-controlled study.

**METHODS**

**Study design and target group**

This prospective, self-controlled, open-label study was conducted in Isfahan endocrine and metabolism research center (IEMRC), Isfahan, Iran during November 2014 to November 2017. We evaluated patients with a probable diagnosis of PHP who were referred to endocrinology clinics of IEMRC. Then, based on clinical, biochemical/hormonal and imaging (ultrasound ± sestamibi scan) assessments, the diagnosis was confirmed and decision for surgery were made based on the last guidelines.\textsuperscript{[13]} The participants were selected based on the following criteria: 1 patient in whom parathyroid adenoma was clearly visible by ultrasound and confirmed by fine-needle aspiration (FNA) and parathyroid hormone (PTH) wash out of the suspected mass, 2 patients who did not accept surgery, or surgery was not an appropriate plan for them,\textsuperscript{[13]} and 3 patients who choose ultrasound-guided parathyroid alcohol ablation. Patients who needed second or third injection, but were not satisfied with the procedure after the first or second time had the option to stop the procedure and to be followed or introduced for the surgery. We explained the protocol of the study to all participants, and a signed written consent was obtained from them. For elderly patients aged more than 70, we also obtained informed consent from their legal caregivers. The study received ethics approval from the Ethics Committee of Isfahan University of Medical Sciences (396431).

**Intervention and measurements**

All percutaneous ethanol injection procedures were performed by two experienced interventional radiologists after FNA biopsy of the suspected mass. The ultrasound characteristics of parathyroid adenomas was usually a single fusiform and well-capsulated nodule, with moderate-to-high vascularity and most of the time significantly hypoechoic. The ultrasonography was performed by Samsung R730 ultrasound. After sterilization of the skin, a small amount of local anesthetic (lidocaine 2%) was injected into subcutaneous tissue before alcohol injection. A 25G needle was used to inject ethanol. Needle of the syringe containing 96% ethanol was inserted into the parathyroid adenoma under the guidance of real-time ultrasonography by the radiologist. Between 3 and 6 mL of ethanol, depending on the vascularity and size of adenomas was injected into the four quadrants of parathyroid adenoma with alcohol diffusion monitoring by ultrasonography. One month after the first injection, ultrasound was repeated. Then, based on the biochemical and sonographic findings, a decision for the second ethanol injection was made. The third and fourth injections were repeated at later months if needed as well.

Serum levels of PTH, calcium, phosphate, 25-OH Vitamin D, and alkaline phosphatase (ALP) were evaluated before, 1 month, 3 months, 6 months, and 1 year after the procedure. Successful ablation was defined by a significant reduction of adenoma size and vascularity on Doppler ultrasonography, decreased level of serum calcium (returning to normal range), and PTH (returning to normal range or more than 50% decrease). The study flow diagram is presented in Figure 1.

Serum calcium was measured by Arsenazo method (normal range: 8.6–10.3 mg/dl). Serum PTH was measured by ELISA (Uroimmune, Deutschland, normal range: 10.9–54.8 pg/dl). Serum 25-(OH) D was measured by ELISA (Biorex fars, Iran, normal range: 20–100 ng/ml). Serum ALP was measured by calorimetry (normal range: 64–306 mg/dl). Serum phosphate was measured by calorimetry (normal range: 2.5–5 mg/dl).

The patients with PHP were defined and categorized in three groups: elevated PTH and high normal serum calcium, elevated serum calcium and high normal PTH and elevated both PTH and serum calcium. To unify these three groups in one group for statistical analysis by the software in a more straightforward way, and as a practical guideline, we also proposed a variable (PTH × serum calcium >550 and serum calcium >9.8 mg/dl) for defining PHP.

**Statistical analysis**

Continuous data were reported as mean ± standard deviation (SD) and categorical data as frequency (percentage). Normality of continuous data was evaluated using the Kolmogorov–Smirnov test and Q-Q plot. Right skewed data were subjected to logarithmic transformation.
Baseline characteristics were compared across age groups by independent sample t-test. To compare the outcome variables between different periods, repeated measures analysis was used. All statistical analyses were conducted using the SPSS software version 20 (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, version 20.0, Armonk, NY, USA: IBM Corp.). The two-tailed \( P < 0.05 \) was considered statistically significant.

### RESULTS

After 1 year follow-up, 39 patients remained in the study that 35 (87.5%) of them were females. The mean age of the participants was 61.28 ± 10.37 years, ranging from 33 to 83 years. Baseline characteristics of the participants are presented in Table 1. About 51.3% of participants were < 60 years old. Adenoma size was slightly larger among older age group (0.82±0.74 cm\(^3\) vs. 2.98±9.21 cm\(^3\), \( P = 0.302 \)). Serum calcium as well was significantly higher in older patients (10.52±0.75 vs. 11.07±0.84, \( P = 0.039 \)). Other characteristics did not show any significance difference between the age groups (\( P > 0.05 \)). Mean 24 h urinary calcium was 267 mg/24 h.

Overall, 26 (66.7%) patients underwent one injection, 8 (20.5%) twice, 4 (10.3%) three times, and one patient (2.6%) four times.

After the injections, mean of the adenoma volume decreased significantly from 1.87±6.45 cm\(^3\) to 0.38±0.48 cm\(^3\) (\( P < 0.001 \)) \([\text{Figure 2}]\).

Table 2 indicates the changes of measured outcomes during the follow-up. Corrected serum calcium levels decreased significantly after the 1\(^{st}\) month and remained stable during 1 year follow-up (\( P < 0.001 \)). Serum PTH as well decreased significantly after the 1\(^{st}\) month and continued to decrease during 1 year follow-up (\( P < 0.001 \)) \([\text{Figure 3}]\). Serum phosphate increased significantly after 3 months and increased gradually after that during the follow-up period (\( P < 0.001 \)). Serum ALP had a non-significant decrease after 3 months and remained stable during the follow-up period (\( P = 0.07 \)). Serum 25-(OH)-Vitamin D increased progressively during the study (by prescribed or personal supplement intake) (\( P < 0.001 \)).

About 46% of the patients with hyperparathyroidism improved after one month of ethanol ablation therapy which increased to 84.5% during 1 year follow-up.

No major complications were observed in the participants during or after ethanol injection and during 1 year of follow-up. Minor complications such as local pain and injection site irritation were observed rarely in some patients, which usually subsided rapidly.

### DISCUSSION

The present study showed that ethanol injection could control hyperparathyroidism in 85% of the patients and decrease...
serum corrected calcium, PTH and adenoma volume in them. Parathyroidectomy, a surgical procedure, is currently the treatment of choice in PHP. If performed by an experienced parathyroid surgeon, parathyroidectomy is curative in 95%–98% of the patients. Despite this high success rate, it might have various complications, such as hematoma and neck swelling, while the ethanol injection method was relatively safe and did not show any major complications.

To the best of our knowledge, there are not enough clinical trials on the ethanol injection for PHP, and only some case reports/series and animal studies have been published. Vergès et al. showed that ultrasound-guided percutaneous ethanol injection of parathyroid adenomas was effective in 64.5% of patients with PHP during the 5-year follow-up. It was very effective in patients with contraindications to the surgery. Another study performed by Cercueil et al. revealed a biochemical recovery (i.e. reduction of plasma calcium and PTH, and increase in serum phosphate levels) of 58%. It also showed only 7% failure rate and finally concluded that acquired results in ethanol injection were remarkable but not as good as surgery method.

Guttin et al. performed a study on the efficacy of percutaneous ultrasound-guided ethanol ablation on the outcomes of 24 dogs with PHP with parathyroid nodules. They showed that ethanol ablation was an effective treatment for those dogs, with lower duration of anesthesia, lower complications, and low risk for hypocalcemia.

Montenegro et al. reported a case with unresectable parathyroid carcinoma who responded to ultrasound-guided ethanol injection. They observed the reduction in PTH levels from 2990 pg/mL to 2230 pg/ml after the first injection, and decreased to 1104 pg/mL after the second injection and reduction in calcium serum levels from 19.8 mg/dL to 16.1 mg/dL and to 14.5 mg/dL, respectively, without serious complication.

Alherabi et al. reported ultrasound-guided ethanol injection of parathyroid adenomas as an alternative to the surgery in patients with significant medical comorbidities. They observed significant response in laboratory tests and clinical findings.

Cappelli et al. reported two cases of PHP with parathyroid adenoma who underwent ultrasound-guided ethanol injection. Both cases showed remarkable response in clinical manifestation and laboratory variables to alcohol injection after 20 months of follow-up.

Harman et al. had reported four indications, including medical comorbidities, patient choice, difficult surgery technically, and partial ablation. Percutaneous alcohol ablation is less expensive, less invasive, with less extensive preparation, and reduces the usual risks of surgery.

Shenoy et al. used radiofrequency ablation followed by percutaneous ethanol ablation for a case. They observed a reduction of adenoma size and a decrease in PTH level after the procedure.
Few complications have been reported with the percutaneous alcohol ablation, including incomplete necrosis of the adenoma, recurrent laryngeal nerve injury, hypocalcemia, and peri-glandular fibrosis, which have not been observed in our study.

Limitations
Our study has some limitations: first, we did not have the control group, and it was an open-label study. As it was a pilot study, we recommend designing an RCT for better evaluation of the method, its efficacy, side effects, and acceptability. Second: duration of follow-up of this study was 1 year, and we do not have sufficient data regarding the recurrence or stability of the condition after that time. Furthermore, we did not include bone mineral density (BMD), because based on the guidelines, it was not mandatory for all the patients. Limited number of participants is another limitation of the present study. We suggest larger and if possible, randomized controlled studies with longer duration of follow-up for better elucidation of this alternative management technique.

CONCLUSIONS
The results of the present study suggest the beneficial effects of ultrasound-guided ethanol injection in controlling PHP due to parathyroid adenoma, which could be considered as a suitable alternative treatment instead of surgery in patients with contraindication for surgery and significantly lead to better control in the short term and increase the quality of life for a long time. Further investigation on a larger sample size of patients is needed to guarantee the efficacy and safety of the proposed procedure in contrast to surgery method for longer periods of follow-up.

Acknowledgments
The present study was financially supported by Vice Chancellor of Research, Isfahan University of Medical Sciences, Isfahan, Iran, and IEMRC. We gratefully acknowledge the dedicated efforts of the coordinators, especially Professor Ashraf Aminorroaya, Atsa Norouzi, and the patients who participated in this study.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Mackenzie-Feder J, Sirrs S, Anderson D, Sharif J, Khan A. Primary hyperparathyroidism: An overview. Int J Endocrinol 2011;2011:251410.
2. Piggott RP, Waters PS, Ashraf J, Colesky F, Kerin MJ. Water-clear cell adenoma: A rare form of hyperparathyroidism. Int J Surg Case Rep 2013;4:911-3.
3. Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005;132:359-72.
4. Kandemir O, Kelkit PA, Karakus K. Synchronous parathyroid adenoma and papillary thyroid carcinoma: 99mTc-MIBI Scan Findings. Niger J Clin Pract 2017;20:1510-2.
5. Matthews C, Matthews A, Safavi K. Clinical images: Four-dimensional computed tomography-future of preoperative parathyroid adenoma imaging. Ochsner J 2017;17:220-2.
6. Chigot JP, Menegaux F, Achorfi H. Should primary hyperparathyroidism be treated surgically in elderly patients older than 75 years? Surgery 1995;117:397-401.
7. Farford B, Presutti RJ, Moraghan TJ. Non-surgical management of primary hyperparathyroidism. Mayo Clin Proc 2007;82:351-5.
8. Rizzoli R, Ammann P. Non-surgical treatment of primary hyperparathyroidism. Acta Endocrinol (Copenh) 1993;129:375-6.
9. Cappelli C, Pelizzari G, Pirola I, Gandossi E, De Martino E, Delbarba A, et al. Modified percutaneous ethanol injection of parathyroid adenoma in primary hyperparathyroidism. QJM 2008;101:657-62.
10. Alherabi AZ, Margiani OA, Alfiky MG, Raslan MM, Al-Shehri B. Percutaneous ultrasound-guided alcohol ablation of solitary parathyroid adenoma in a patient with primary hyperparathyroidism. Am J Otolaryngol 2015;36:701-3.
11. Cercueil JP, Jacob D, Verges B, Holtzmann P, Lerais JM, Krause D. Percutaneous ethanol injection into parathyroid adenomas: Mid- and long-term results. Eur Radiol 1998;8:1565-9.
12. Stratigis S, Stylianou K, Mamalaki E, Perakis K, Vardaki E, Tzenakis N, et al. Percutaneous ethanol injection therapy: a surgery-sparing treatment for primary hyperparathyroidism. Clin Endocrinol (Oxf) 2008;69:542-8.
13. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Uedelsman R, Marcocci C, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561-9.
14. Iglesias P, Diez JJ. Current treatments in the management of patients with primary hyperparathyroidism. Postgrad Med J 2009;85:15-23.
15. Meltzer C, Klau M, Gurushanthaiah D, Titan H, Meng D, Radler L, et al. Risk of complications after thyroidectomy and parathyroidectomy: A case series with planned chart review. Otolaryngol Head Neck Surg 2016;155:391-401.
16. Vergés B, Cercueil JP, Jacob D, Vaillant G, Brun JM. Treatment of parathyroid adenomas with ethanol injection under ultrasonographic guidance. Ann Chir 2000;129:375‑6.
17. Guttin T, Knox VW 4th, Drioff JS. Outcomes for dogs with primary hyperparathyroidism following treatment with percutaneous ultrasound-guided ethanol ablation of presumed functional parathyroid nodules: 27 cases (2008-2011). J Am Vet Med Assoc 2015;247:771-7.
18. Montenegro FL, Chammas MC, Juliano AG, Cernesa CR, Cordeiro AC. Ethanol injection under ultrasound guidance to palliate unrespectable parathyroid carcinoma. Arq Bras Endocrinol Metabol 2008;52:707-11.
19. Harman CR, Grant CS, Hay ID, Hurley DL, van Heerden JA, Thompson GB, et al. Indications, technique, and efficacy of alcohol injection of enlarged parathyroid glands in patients with primary hyperparathyroidism. Surgery 1998;124:1011-9.
20. Shenoy MT, Menon AS, Nazar PK, Moorthy S, Kumar H, Nair V, et al. Ethanol ablation of parathyroid adenoma: A pilot study. Eur J Endocrinol 2011;2011:251410.
21. Guttin T, Knox VW 4th, Drioff JS. Outcomes for dogs with primary hyperparathyroidism following treatment with percutaneous ultrasound-guided ethanol ablation of presumed functional parathyroid nodules: 27 cases (2008-2011). J Am Vet Med Assoc 2015;247:771-7.
22. Montenegro FL, Chammas MC, Juliano AG, Cernesa CR, Cordeiro AC. Ethanol injection under ultrasound guidance to palliate unrespectable parathyroid carcinoma. Arq Bras Endocrinol Metabol 2008;52:707-11.
23. Harman CR, Grant CS, Hay ID, Hurley DL, van Heerden JA, Thompson GB, et al. Indications, technique, and efficacy of alcohol injection of enlarged parathyroid glands in patients with primary hyperparathyroidism. Surgery 1998;124:1011-9.
et al. Radiofrequency ablation followed by percutaneous ethanol ablation leading to long-term remission of hyperparathyroidism. J Endocr Soc 2017;1:676-80.

21. Chen HH, Hsu MT, Wu CJ, Chen YW, Yang TL. Effects of percutaneous ethanol injection therapy on subsequent parathyroidectomy. Am J Surg 2008;196:155-9.

22. Veldman MW, Reading CC, Farrell MA, Mullan BP, Wermers RA, Grant CS, et al. Percutaneous parathyroid ethanol ablation in patients with multiple endocrine neoplasia type 1. AJR Am J Roentgenol 2008;191:1740-4.